16 мая 2024 г. · Resmetirom is the first MASH therapy to be approved by the US Food & Drug Administration, a substantial breakthrough. Rates of cirrhosis ...

Resmetirom is the first MASH therapy to be approved by the US Food & Drug Administration, a substantial breakthrough. Rates of cirrhosis among people with ...

Resmetirom for MASH-related cirrhosis. Lancet Gastroenterol Hepatol. 2024 Jul;9(7):594. doi: 10.1016/S2468-1253(24)00124-9.

21 окт. 2024 г. · The MAESTRO-NASH OUTCOMES trial evaluating resmetirom for the treatment of patients with compensated NASH cirrhosis has completed enrollment.

Resmetirom therapy was associated with a statistically significant reduction in atherogenic lipids and liver enzymes at Week 36. Resmetirom significantly ...

19 апр. 2024 г. · The current registrational trial of resmetirom excluded people with cirrhosis, children and women of child-bearing age who may be planning a ...

14 мар. 2024 г. · The US Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

28 мар. 2024 г. · The drug, resmetirom, has also been shown in clinical trials to reduce scar tissue, or fibrosis, in the liver and to lower cholesterol levels.

20 июл. 2024 г. · Although resmetirom is likely safe in such patients, the drug should not be used in patients diagnosed with or suspected to have cirrhosis until ...

21 мар. 2024 г. · This is a multi-national, multicenter, double-blind, randomized, placebo-controlled study in participants with well-compensated NASH cirrhosis.